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Abstract 
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Alzheimer’s disease (AD) is a neurodegenerative disorder leading to a progressive loss 
of cognitive function and is pathologically characterized by senile plaques and 
neurofibrillary tangles (NFTs). Microtubule-associated protein tau (MAPT) is a major 
constituent of NFTs, and its hyperphosphorylation is considered one of causes of AD. 
Mutations in the MAPT gene are known to cause familial neurodegenerative diseases 
such as frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17). The purpose of this study was to understand the mechanism of tau 
neurotoxicity and to discover a tau-targeting drug. I generated a novel mouse model of 
tauopathy harboring mutant tau and clarified etiology of tau in neurodegenerative 
diseases. And, I discovered a drug inhibiting tau phosphorylation and assessed its 
therapeutic efficacy in AD mouse model.  
In the first chapter, I describe a transgenic mouse, named TPR50, harboring human 
tau with an FTDP-17 mutation P301S. TPR50 mice exhibited age-related increase in 
tau phosphorylation in the hippocampus. Insolubilization and intracellular 
accumulation of tau were observed in the hippocampus by 9 months of age. While, 
behavioral function related to cognition and memory was already impaired at earlier 
age. At that age, decrease in axonal transport in the septo-hippocampal pathway was 
observed, and expression of microtubule (MT)-related proteins and MT hyperdynamics 
in the hippocampus were abnormally increased. They might account for behavioral 
dysfunction, suggesting that impaired axonal function rather than accumulation of 
insoluble tau may be linked with neural dysfunction in TPR50 mice. TPR50 mouse is a 
valuable model to study progression of tauopathies.  
In the second chapter, I describe a novel glycogen synthase kinase-3 (GSK-3) inhibitor 
that suppresses tau phosphorylation. By high-throughput screening and chemical 
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modification, I found 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)- 
1,3,4-oxadiazole (MMBO), which displays high selectivity for GSK-3 and brain 
penetration following oral administration. When administered to a transgenic mouse 
model of AD, MMBO significantly decreased phosphorylated tau in the hippocampus. 
Chronic administration of MMBO suppressed tau pathology as assessed by 
immunoreactivity of AT8, which is a phophorylated tau antibody. In addition, MMBO 
significantly improved memory and cognitive deficits in the AD mouse model. These 
results indicate that pharmacological GSK-3 inhibition ameliorates behavioral 
dysfunction with suppression of tau phosphorylation in an AD mouse model. 
Taken together, I conclude that improvement of axonal dysfunction due to abnormal 
tau is a novel therapeutic concept in neurodegenerative diseases such as AD, and 
inhibition of tau phosphorylation is a promising approach based on the concept. 
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Aβ           amyloid β 
AD          Alzheimer’s disease 
FTDP-17     frontotemporal dementia with parkinsonism linked to chromosome 17 
FTLD        frontotemporal lobar degeneration 
GSK-3       glycogen synthase kinase-3 
MT          microtubule 
NFTs        neurofibrillary tangles 
PHFs        paired helical filaments 
SEM        standard error of the mean 
Tg          transgenic 
WT         wild type 
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General Introduction 
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Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 
60-80% of dementia cases (alz.org: alzheimer's association a). In Japan more 4.6 
million people are living with dementia. And this number is expected to rise 
significantly because Japan is facing unprecedented aging society (alz.org: alzheimer's 
association b). Worldwide, over 46 million people are estimated to be living with 
dementia, and the number of people with dementia is predicted to reach 74.7 million by 
2030 and 131.5 million by 2050, if effective disease modifying therapies are not 
developed (Alzheimer's Disease International: World Alzheimer Report 2015). Current 
available therapies for AD only provide symptomatic relief and cannot suppress or halt 
disease progression. A disease modifying therapy, which is based on pathomechanism of 
AD, becomes a central focus of drug discovery. Therefore, there is a pressing need to 
understand pathogenesis more deeply for developing disease modifying therapies.  
The two core pathological hallmarks of AD are senile plaques and neurofibrillary 
tangles (NFTs). And, targeting these pathologies has been developed as therapeutic 
approaches. In the original hypothesis, senile plaques consisting of amyloid β (Aβ) was 
thought to trigger neuronal dysfunction. The fact that mutations in APP, PSEN1, and 
PSEN2 genes, which code proteins involved in Aβ production, cause familial types of AD 
would support the hypothesis. However, several drug candidates targeting Aβ have 
failed in clinical trials recently, and many researchers now believe that those 
intervention was too late, and treatments that target Aβ should be tested in earlier 
stage of the disease rather than in late-stage disease (Golde et al., 2011). In contrast, 
recent study using large number of postmortem brains clearly showed NFT formation is 
strongly linked with disease progression such as disease onset and cognitive decline in 
AD as a driver (Murray et al., 2015). Therefore, interest in NFT and its constituent 
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microtubule (MT)-associated protein tau as a drug target is increasing. In diseased 
brain, tau is abnormally hyperphosphorylated at specific sites (Grundke-Iqbal et al., 
1986; Friedhoff et al., 2000), and  hyperphosphorylation of tau is thought to result in 
its pathological aggregation forming NFTs. Ultrastructural studies on AD brain 
specimens revealed that NFTs are primarily made of paired helical filaments (PHFs), 
that is, fibrils of 10 nm in diameter that form pairs with a helical tridimensional 
conformation at a regular periodicity of  65 nm (Kidd, 1963, 1964; Wisniewski et al., 
1976). This aggregate can stress out neurons. While, tau functions as a modifier of MT 
stability under physiological condition (Drechsel et al., 1992; Lee et al., 1998; Dixit et al., 
2008). Hyperphosphorylation of tau reduces the binding to MT. Consequently, the 
increased pool of soluble tau may trigger the disintegration of MTs (Grundke-Iqbal et al., 
1986; Goedert et al., 1995). Actually, invariably accompanying NFTs are the neuropil 
threads, which are thought to result from the breakdown of dendrites and axons of the 
tangle-bearing neurons, suggesting that dysregulation of tau might cause MT 
abnormality. Moreover, interestingly, mutations in the coding and intronic regions of 
MAPT, the gene encoding tau, are known to cause familial forms of neurodegenerative 
disease named FTDP-17 which is adjacent to AD (Hutton et al., 1998; Poorkaj et al., 
1998; Spillantini et al., 1998). Taken together, understanding mechanism underlying 
pathogenesis of tau is valuable for discovering a novel therapeutic strategy in 
neurodegenerative disease including AD.  
Here I summarize my findings on detailed mechanism of tau toxicity and therapeutic 
strategy of tau-targeting drug by using animal models. In part 1, I generated novel Tg 
mice (TPR50) expressing human tau with a P301S mutation and assessed the 
biochemical and behavioral phenotypes. The P301S mutation is one of the major 
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mutations in FTDP-17, and is linked with early onset of disease progression and strong 
functional influences (Bugiani et al., 1999; Goedert et al., 1999; Yasuda et al., 2000; 
Lossos et al., 2003; Werber et al., 2003). In second part, I report therapeutic potential of 
the drug targeting tau in AD mouse model. As described above, hyperphosphorylation of 
tau is thought to result in its pathological aggregation and phosphorylation is 
contributed by some kinases. GSK-3 is reported to phosphorylate tau affecting 
microtubule rearrangement in vitro (Lovestone et al., 1996; Wagner et al., 1996) and 
also to be associated with NFTs in AD (Pei et al., 1997 and 1999), suggesting that 
inhibition of GSK-3 is a good therapeutic target. In this study, I discovered a novel 
selective GSK-3 inhibitor, and validated its potential in an AD mouse model.   
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Part I 
Early-Onset Cognitive Deficits and Axonal Transport Dysfunction in P301S Mutant Tau 
Transgenic Mice 
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Abstract 
 
AD and FTLD are neurodegenerative “tauopathies” characterized by 
hyperphosphorylated tau accumulation and NFTs. The P301S mutation of tau, a causal 
mutation of a familial type of FTLD, is believed to be involved in neurodegenerative 
progression. I developed a transgenic mouse, named TPR50, harboring human P301S 
tau. Tau phosphorylation in the hippocampus of TPR50 mice increased with age, 
particularly at S202/T205. Insolubilization and intracellular accumulation of tau were 
detected in the hippocampus by 9 months of age. Expression of calbindin was 
significantly reduced in 6- and 9-month-old TPR50 mice but not in 3-month-old mice. 
TPR50 mice demonstrated cognitive dysfunction at 5 months. At this age or earlier, 
although no intracellular tau accumulation was observed in the hippocampus, 
abnormally increased MT-related proteins and MT hyperdynamics in the hippocampus, 
and impaired axonal transport in the septo-hippocampal pathway were already 
observed. Therefore, cognitive dysfunction in TPR50 mice may result from early MT 
dysfunction and impaired axonal transport rather than accumulation of insoluble tau 
and neurodegeneration. TPR50 mice are a valuable new model to study progression of 
tauopathies at both the behavioral and neurocellular levels and may also prove useful 
for testing new therapies for neurodegenerative diseases.  
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Introduction 
 
NFT, consisting of the MT-associated protein tau are a pathological hallmark of AD 
and FTLD such as Pick disease, progressive supranuclear palsy, and corticobasal 
degeneration (Goedert et al., 1988; Lee et al., 2001). The strong temporal correlation 
between NFT formation, neurodegeneration, and symptom progression indicates that 
tau is a key molecule in disease pathogenesis. Indeed, these diseases are collectively 
termed tauopathies.  
Under physiological conditions, tau functions as a modifier of MT stability (Drechsel et 
al., 1992; Lee et al., 1998; Dixit et al., 2008). Hyperphosphorylation of tau reduces the 
binding to MT. Consequently, the increased pool of soluble tau may trigger the 
disintegration of MTs (Grundke-Iqbal et al., 1986; Goedert et al., 1995). Mutations in 
the coding and intronic regions of MAPT, the gene encoding tau, are known to cause 
familial forms of FTLD (FTDP-17) (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini 
et al., 1998). Several mutant tau transgenic (Tg) mouse lines have been generated to 
model tau pathology and neurodegenerative phenotypes (Götz and Ittner, 2008), some of 
which exhibit abnormal tau accumulation and impaired axonal function (Lewis et al., 
2000; Zhang et al., 2004; Ittner et al., 2008).  
In humans, the P301S mutation causes early onset of disease progression and strong 
functional influences (Bugiani et al., 1999; Goedert et al., 1999; Yasuda et al., 2000; 
Lossos et al., 2003; Werber et al., 2003). Biochemical studies have shown that the P301S 
mutation reduces the ability of MT assembly (Bugiani et al., 1999) and enhances 
heparin-induced tau filament formation (Goedert et al., 1999). Two lines of Tg mice 
expressing P301S mutant 4R0N and 4R1N tau isoforms have been reported (Allen et al., 
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2002; Yoshiyama et al., 2007), and both lines develop NFT-like pathology and 
neurodegeneration. Memory impairment was also reported in one of these lines 
(Takeuchi et al., 2011). However, definitive mechanism of toxicity by mutant tau is still 
unclear. Therefore, I conducted this study in order to understand a pathophysiological 
role of tau in disease progression. I generated novel Tg mice (TPR50) expressing the 
longest form (4R2N) of tau with a P301S mutation and assessed the biochemical and 
behavioral phenotypes to further investigate the mechanisms underlying 
age-dependent tau accumulation, neurotoxicity, and behavioral sequelae. I also 
examined tau pathophysiology, neural function, MT-related proteins, and axonal 
function of TPR50 mice by behavioral and biochemical approaches. These mice 
exhibited age-dependent abnormal tau accumulation and motor deficits as expected. In 
addition, they showed early-onset of cognitive impairment and disrupted axonal 
transport in the septo-hippocampal pathway.  
 
  
14 
 
Materials and Methods 
 
Animals 
TPR50 mice were generated by microinjection of a vector encoding a P301S mutant of 
the longest human tau isoform (4R2N) under the control of the mouse prion promoter 
(Supplementary Figure 1) into single-cell embryos harvested from BDF1 mice and then 
backcrossed more than 10 times with C57BL/6J mice. Only male mice were used in this 
study. They were housed in groups and kept on a 12h-light/12h-dark schedule and 
provided ad libitum access to food and water. All animals were maintained and 
sacrificed according to the guidelines of the Takeda Experimental Animal Care and Use 
Committee.  
 
Antibodies 
Antibodies against the following proteins were used in this study: AT270, AT8, HT7 
(Innogenetics, Ghent, Belgium), pS214-tau, pS262-tau, pS396-tau (Invitrogen, Carlsbad, 
CA, USA), Ab-3 (Thermo Fisher Scientific, Fremont, CA, USA), synaptophysin, 
acetylated tubulin, α-tubulin, β-actin (Sigma, St. Louis, MO, USA), synaptotagmin 
(Enzo, New York, NY, USA), kinesin heavy chain, PSD-95, and calbindin (Millipore, 
Bedford, MA, USA).  
 
SDS-PAGE and Western blotting 
Hippocampi isolated from Tg and WT mice were homogenized in lysis buffer (50 mM 
Tris-HCl, 5 mM EDTA, 1 mM EGTA, 100 mM NaCl, 1% NP-40, and 2.5% sodium 
deoxycholate, pH7.5) supplemented with protease inhibitors [1.37 mg/L pepstatin A, 25 
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KIU/mL aprotinin, 1 nM microcystin LR, 1 nM MG115, 40 nM leupeptin and 100 nM 
4-(2-aminoethyl)benzenesulfonyl fluoride (ABSF) HCl] and phosphatase inhibitors (30 
mM NaF, 5 mM sodium diphosphate, and 2 nM sodium orthovanadate). The 
homogenate was centrifuged at 10,000 g for 10 minutes and the supernatant taken as 
the soluble protein fraction. Total protein concentration was determined using the BCA 
assay kit (Pierce, Rockford, IL, USA). Equal amounts of protein (1-20 μg depending on 
the protein of interest) were separated by SDS-PAGE on 10% polyacrylamide gels, then 
electrophoretically transferred to 0.45 μm poly-vinylidene difluoride membranes 
(Millipore) and blocked for 1 h in BlockAce (DS Pharma Biomedical, Osaka, Japan). 
After blocking, the membranes were probed with primary antibodies followed by 
labeling with horseradish peroxidase (HRP)-coupled secondary antibodies (Amersham, 
Piscataway, NJ, USA). Immunolabeling was visualized by a chemiluminescence reagent 
(Immunostar; Wako, Osaka, Japan) using a LAS1000 imaging system (Fujifilm, Tokyo, 
Japan) or ImageQuant LAS4000 (GE healthcare, Pittsburgh, PA, USA). Quantitative 
densitometric analyses were performed with Image Gauge (Fujifilm) or ImageQuant TL 
(GE healthcare). Values presented are derived from densitometry arbitrary units (A.U.). 
With regard to immunoblot of tau, the bands including all tau species were selected and 
analyzed.  
 
Preparation of insoluble tau 
Insoluble aggregated tau was prepared by the sarkosyl extraction methods, described 
previously (Sahara et al., 2004; Taniguchi et al., 2005; Uno et al., 2009). In brief, lysis 
buffer-insoluble pellets were rehomogenized with 0.5 M NaCl containing 10% sucrose 
and incubated in 1% sarkosyl for 1 h at 37°C. After centrifugation at 256,000 g for 15 
16 
 
minutes, the pellets were resuspended by ultrasonication in phosphate buffered saline 
to yield the sarkosyl insoluble fraction.  
 
RAB-RIPA-formic acid (FA) extraction 
RAB-RIPA-FA extraction was performed by using a previously described method 
(Ishihara et al., 1999, 2001; Eckermann et al., 2007; Uno et al., 2009). Brain tissue was 
homogenized in ice-cold high-salt RAB buffer [0.1 M morpholineethanesulfonic acid 
(MES), 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 100 μM ABSF, and 
protease inhibitors (Complete Mini, Roche Applied Science, Mannheim, Germany), pH 
7.0], and the sample was centrifuged at 50,000 g for 20 minutes at 4°C. The supernatant 
was boiled for 5 minutes and then centrifuged at 10,000 g for 20 minutes at 4°C. The 
resulting supernatant contains the soluble tau fraction (RAB fraction). To remove 
myelin and associated lipids, RAB insoluble pellets were re-extracted with 1 M 
sucrose/RAB buffer and centrifuged at 100,000 g for 30 minutes at 4°C. The pellets were 
suspended in RIPA buffer (50 mM Tris–HCl, 5 mM EDTA, 1 mM EGTA, 30 mM NaF, 5 
mM sodium diphosphate, 2 μM pepstatin A, 100 mM NaCl, 1% NP-40, 0.25% sodium 
deoxycholate, 1 μM microcystin LR, 40 μM leupeptin, 100 μM ABSF, 2 mM sodium 
orthovanadate, 1 μM MG115, pH 7.6) and centrifuged as mentioned above to obtain the 
supernatants (RIPA fraction). Finally, the RIPA insoluble pellets were re-extracted with 
70% FA.  
 
Immunohistochemistry 
Dissected hemibrains were fixed in 4% paraformaldehyde (Wako) for 24 h. Fixed 
hemibrains were embedded and frozen in freezing medium (OCT Tissue-Tek 4583; 
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Sakura Finetechnical, Tokyo, Japan) and sliced into 20-μm-thick sections using a 
cryostat (CM1850; Leica, Nussloch, Germany). These sections were mounted onto 
silane-coated slides (Matsunami, Osaka, Japan). After blocking with BlockAce 
containing 3% fetal bovine serum, the slides were probed with a primary antibody 
against total tau (HT7, 1:2000 dilution), followed by an HRP-coupled secondary 
antibody (Dako, Glostrup, Denmark). Immunolabeling was detected by 
3,3’-diaminobenzidine tetrahydrochloride staining (Dako). Images were captured using 
Nanozoomer and NDP scan software (Hamamatsu Photonics, Hamamatsu, Japan).  
 
Bielschowsky silver staining 
Bielschowsky silver staining was performed as described previously (Bellucci et al., 
2006), with minor modifications. The dissected brain was fixed in 4% paraformaldehyde 
(Wako) for 24 h. The right hemisphere was cut in the coronal plane and the left 
hemisphere was cut in the sagittal plane. Samples were embedded in paraffin and cut 
into 4-μm-thick sections. After deparaffinization, the sections were stained with 20% 
silver nitrate solution for 20 minutes, rinsed in distilled water, and stained with 
ammonium silver solution for 20 minutes. After washing with 0.1% ammonium 
hydroxide solution, the sections were put in ammonium silver solution containing 
formaldehyde, monohydrate citric acid, and concentrated nitric acid for optimal staining. 
The sections were then rinsed three times in distilled water, placed in 5% sodium 
thiosulfate solution for 5 minutes, dehydrated through increasing concentrations of 
ethanol and xylene, and assembled.  
 
Behavioral assessments 
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Y-maze: The Y-maze has three arms, 42 cm in length and 3 cm in width, projecting at 
equal angles and all colored black (BrainScience Idea, Osaka, Japan). The walls of the 
maze are 12-cm tall, and angled at 16.25° from the vertical. Mice were initially placed 
within one arm, and the sequence and number of arm entries were recorded for each 
mouse over a period of 8 minutes. An arm choice was defined as both forepaws and 
hindpaws fully entering the arm. The device was cleaned with 10% ethanol between 
trials. The percentage of triads in which all three arms were entered (ABC, CAB, or 
BCA but not BAB) was recorded as a spontaneous alternation to estimate short-term 
memory. In addition, the number of total arm entries served as an indicator of general 
locomotor activity. 
Novel object recognition: The box and objects used were purchased from BrainScience 
Idea (Osaka, Japan). The box was 30 × 30 × 30 cm and colored neutral gray. The two 
acquisition trial objects (object A and A*) were white ceramic cylinders and the novel 
object (B) was a black wooden rectangular parallelepiped. In the acquisition test, the 
identical objects (objects A and A*) were symmetrically placed in the box. Each animal 
was placed in the corner of the box with head turned toward the wall and allowed 5 
minutes of exploration. The devices were cleaned with 10% ethanol between trials. The 
retention test was administered 24 h later. After replacing one of the objects with a 
novel object (object B), mice were reintroduced into the box for a 5-minute retention test. 
The time spent exploring the objects and the number of approaches was measured 
during both tests. Retention was represented by how long the animals explored the 
novel object versus the familiar object (exploratory preference).  
Rotarod: The apparatus consisted of a bar, which was 3.0 cm in diameter and 40 cm in 
length and was subdivided into five areas by disks (Muromachi Kikai, Tokyo, Japan). 
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The mice were given a 300-s training session on the rotating rod at 4 rpm 1 day before 
the three test trials. Each mouse was placed on the rotating rod with its head pointed in 
the direction opposite that of rotation so that the mouse progressed forward to maintain 
balance. Each trial for each mouse was separated by 1 h. The apparatus was cleaned 
with 10% ethanol between trials. During the testing phase, the mice were subjected to 
three consecutive trials at 10 rpm over 180 s and the mean latency to fall was recorded. 
 
MT dynamics assay 
The methods used for in vivo measurements of MT dynamics included 2H isotope 
labeling and application of the KineMed proprietary biomarker platform, as previously 
described (Fanara et al., 2007; Fanara et al., 2010; Barten et al., 2012; Fanara et al., 
2012).  
 
Evaluation of axonal transport 
Retrograde axonal transport was monitored by injection of 0.5 μL of 5% Fluoro-Gold 
(Fluorochrome, Denver, CO) into the hippocampus. The injection site was AP -2.3 mm, 
ML -2.0 mm, and DV -2.0 mm relative to bregma. Three days after the injection, the 
mice were anesthetized and transcardially perfused with phosphate-buffered saline (pH 
7.4), and then 4% paraformaldehyde. Fixed brains were embedded and frozen in 
freezing medium and sliced into 20-μm-thick sections using a cryostat. The sections 
including the medial septum (1.10 mm relative to bregma) were selected and mounted 
onto silane-coated slides with mounting medium (VECTASHIELD; VECTOR, 
Burlingame, CA) and coverslipped. Images were captured using an ECLIPS E800M 
microscope (Nikon, Tokyo, Japan) and a camera (DXM1200, Nikon). Fluorescent cells in 
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the medial septum were counted with Image-Pro Plus software (Media Cybernetics, 
Rockville, MD, USA).  
 
Statistical analysis 
Data are expressed as mean ± SEM and were analyzed by Student’s t-tests or Welch’s 
test for comparisons between WT and Tg mice. p ≤ 0.05 was considered statistically 
significant. Student’s t-tests were also used for comparisons in the novel object 
recognition test. Analyses were performed using SAS system 8 software (SAS Institute, 
Cary, NC, USA).  
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Results 
 
Human tau expression and phosphorylation in TPR50 mice 
To examine tau-induced toxicity in vivo, I generated Tg mice expressing human P301S 
tau under the control of the mouse prion promoter. I established 7 lines of Tg mice 
(TPR16, 50, 56, 72, 82, 96, and 100, Supplementary Figure 1). The line with the highest 
P301S tau expression (TPR50) was backcrossed more than 10 times with C57BL/6J 
mice, and used in this study because it was expected to display the most severe 
phenotypes. These TPR50 mice expressed human mutant tau throughout the brain 
(Figure 1A). Motor deficits were observed at 8.5 months of age but not at 5 months 
(Figure 1B). When lifted by the tail, these mice crossed their hind limbs, a behavior 
endophenotype of tauopathy-associated motor dysfunction. In addition to motor deficits, 
TPR50 mice had a lower mean body weight than age-matched WT mice, and this 
difference increased with age (Figure 1C). Moreover, life expectancy was reduced in Tg 
mice (Supplementary Figure 2). To evaluate the phosphorylation state of human tau, 
total proteins were isolated from the hippocampi of 9.5-month-old TPR50 and WT mice 
and analyzed by Western blotting and densitometry (Figure 2A). Quantitative analysis 
revealed significant increase in total human tau expression in the hippocampus of 
TPR50 mice (Figure 2G). In addition, human tau in Tg mice was phosphorylated at 
T181, S202/T205, S214, S262, and S396, sites that are often phosphorylated in human 
disease (Figures 2A–F). To examine whether phosphorylation status is age-dependent, 
pS202/pT205-, pS262-, and pS396-tau expression levels were examined in 3-, 6-, and 
9-month-old TPR50 and WT mice. Although total tau expression was similar at every 
age (Figure 3E), pS202/pT205-tau increased progressively with age in TPR50 mice 
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(Figure 3B). In addition, tau phosphorylated at S262 and S396 also increased slightly 
with age in Tg mice, although the extent of increase was less than that of 
pS202/pT205-tau (Figures 3C and 3D).  
 
Age-dependent intracellular accumulation and insolubilization of tau in TPR50 mice 
Accumulation of filamentous tau in NFTs is a characteristic feature of 
neurodegenerative tauopathies, and some studies reported that tau transgenic mouse 
models do exhibit age-dependent NFT-like inclusions (Götz and Ittner, 2008). We 
measured age-dependent tau accumulation in the sarkosyl-insoluble protein fractions 
from the hippocampus of TPR50 mice. Sarkosyl-insoluble tau was first detected in 
3-month-old mice, although this was only slightly detected with no significant difference 
between WT and Tg mice and increased progressively with age (Figures 4A and E). Tau 
proteins phosphorylated at S202/T205, S262, and S396 were also detected in the 
sarkosyl-insoluble fraction (Figures 4A‒D). The results of RAB-RIPA-FA extraction also 
revealed a progressively age-dependent increase in insoluble pS202/pT205-tau in 
TPR50 mice (Supplementary Figure 3). These phenotypes suggest age-dependent, 
tauopathy-like tau accumulation in TPR50 mice. Intracellular tau accumulation was 
examined by immunohistochemical analysis (Figure 5). Tau accumulation was observed 
in hippocampal sections from 9-month-old TPR50 mice (Figures 5C and F) but not in 
sections from 6-month-old TPR50 mice (Figures 5B and E), although 6-month-old mice 
expressed comparable levels of soluble tau (Figure 3E).  
 
Cognitive impairments in TPR50 mice 
I examined cognitive function in 5-month-old TPR50 mice, an age at which no 
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significant motor deficits were observed (Figure 1B). In the Y-maze test of short-term 
spatial memory, spontaneous alternation behavior was significantly impaired in TPR50 
mice (Figure 6A). Total arm entries were comparable between WT and Tg mice, 
indicating no severe motor deficits at this age. The motor phenotype comparable to WT 
was also confirmed by the rotarod test (Supplementary Figure 4). In the novel object 
recognition test (Figure 6B), both WT and Tg mice demonstrated comparable 
exploratory activity around both trial objects (objects A and A*), although Tg mice 
tended to explore objects for longer period than WT mice. After a 24-hour delay, object 
A* was replaced with a novel object (B) and the relative time exploring the new vs. 
familiar object (A) was used as a measure of object recognition. TPR50 mice showed less 
exploratory preference for the novel object than for the previously presented object 
compared with WT mice. These results indicate that TPR50 mice have impairments in 
cognitive function as early as 5 months of age.  
 
Alteration of MT-related proteins and neuronal markers in TPR50 mice 
To biochemically examine neural function of TPR50 mice, several proteins involved in 
MT stabilization or synaptic function were evaluated by Western blotting (Figure 7). 
Expression of MT-related proteins such as α-tubulin, its acetylated form, and kinesin 
heavy chain (KHC) were significantly higher in the hippocampus of TPR50 mice 
(Figures 7B‒D). These increases were similarly observed in 3-, 6-, and 9-month-old Tg 
mice. Simultaneously, neuronal markers such as calbindin, synaptophysin, 
synaptotagmin, and PSD-95 were also examined. Expression of calbindin was 
comparable between 3-month-old WT and Tg mice but significantly reduced in 6- and 
9-month-old TPR50 mice (Figure 7E). With regard to the expression of synaptophysin, 
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synaptotagmin, and PSD-95 at up to 9 months of age, there was no significant 
difference between WT and Tg mice (Figures 7F-H).  
 
MT hyperdynamics and impaired axonal transport in TPR50 mice 
Western blotting demonstrated abnormal expression levels of several MT-related 
proteins in TPR50 mice, suggesting possible changes in MT polymerization and 
depolymerization (MT dynamics). MT dynamics in 4- and 7-month-old TPR50 and WT 
mice were assessed in vivo by measuring 2H label incorporation into newly synthesized 
MTs. Although no changes in MAP2-associated MT dynamics were observed in 
4-month-old TPR50 mice, the dynamics of tau-associated MTs were accelerated in both 
the cortex and hippocampus (but not the cerebellum) (Figures 8A‒C). Similarly, the 
dynamics of tau-associated MTs were also accelerated in 7-month-old Tg mice (Figures 
8D‒F). A significant increase in MT dynamics was observed in the MAP2-associated 
fraction from the cortex and hippocampus of TPR50 mice at this age, and cold stable 
(CS)-MTs were significantly increased in the cortical fraction.  
To examine whether axonal transport in the septohippocampal pathway was impaired 
in TPR50 mice, the retrograde tracer Fluoro-Gold was injected in the hippocampus of 
5-month-old TPR50 and WT mice, and fluorescent dye accumulation was measured in 
the medial septum (Supplementary Figure 5). The age of 5 months was selected for 
evaluation because obvious memory and cognitive abnormality was already observed at 
this age (Figure 6). Consistent with disrupted axonal transport in this pathway, TPR50 
mice exhibited significantly fewer labeled septal cells than WT mice (Figure 9).  
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Discussion 
 
I report the generation and characterization of TPR50, a novel transgenic mouse 
expressing a human P301S mutant 4R2N tau, and demonstrate that TPR50 is a robust 
model of progressive neurocellular and behavioral deficit characteristics of human 
tauopathies. I examined age-related pathophysiology including tau accumulation and 
neuronal dysfunction in TPR50 mice to confirm that these mice demonstrate similar 
age-dependent neurocellular deficits and behavioral endophenotypes as previous tau 
mutant mice. This information would be useful for understanding pathogenesis of 
human disease and for translational study in drug discovery. 
Expression of P301S human tau in TPR50 mice was controlled by the mouse prion 
promoter, allowing expression throughout the brain (Figure 1B). Total human mutant 
tau expression in TPR50 mice was significantly increased compared with endogenous 
wild type mouse tau (Figures 2 and 3). This overexpressed human tau was 
phosphorylated at multiple sites (T181, S202/T205, S214, S262, and S396) that are 
known to be phosphorylated in diseased human brains (Friedhoff et al., 2000) (Figure 2). 
Tau phosphorylation increased with age at some residues in TPR50 mice, particularly 
at the AT8-reactive site (Figure 3). Together with increasing tau phosphorylation in 
TPR50 mice, I observed age-dependent formation of insoluble tau in TPR50 mice over 
3‒9 months of age (Figure 4). As expected from previous studies on other mutant tau Tg 
mice (Yoshiyama et al., 2007), insoluble tau was also phosphorylated. It has been 
proposed that phosphorylated tau dissociates from MTs and that these free tau 
molecules then form aggregates that ultimately lead to NFTs and neuronal destruction 
(Götz and Ittner, 2008). Indeed, histological analysis using anti-human tau antibody 
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revealed that tau accumulation is age-dependent (Figure 5). Intracellular tau 
accumulation was detected at 9 months of age, while 6-month-old TPR50 mice did not 
show obvious tau accumulation. Bielschowsky silver staining was also examined and 
revealed a tangle-like pathology in the hippocampus of 9-month-TPR50 mice 
(Supplementary Figure 6).  
Expression of calbindin was significantly lower in 6- and 9-month-old TPR50 mice 
than in WT mice, while the expression was comparable between these two types of mice 
at 3 months of age (Figure 7E). Reduced calbindin expression was reported to be an 
early sign of neurodegeneration in human AD patients (Iritani et al., 2001; Riascos et al., 
2011), underscoring the value of TPR50 mice for modeling the early progression of 
neurodegenerative disease. In contrast, expression of other neuronal markers, including 
synaptophysin, synaptotagmin, and PSD-95, did not decrease even at 9 months of age 
(Figures 7F–7H). This observation indicates that TPR50 mice do not have substantial 
neurodegeneration in the hippocampus by 9 months of age and may also support the 
idea that decrease in calbindin is an early sign of neurodegeneration. 
Motor deficits are observed in most tau Tg mouse models, although the age of 
sideration varies (Lewis et al., 2000; Yoshiyama et al., 2007; Ittner et al., 2008). In this 
mouse model, deficits were observed at 8.5 months of age (Figure 1). Some transgenic 
tauopathy models also demonstrated memory dysfunction prior to detectable neuron 
loss or NFT formation (SantaCruz et al., 2005; Ittner et al., 2008; Takeuchi et al., 2011; 
Flunkert et al., 2012). Similarly, TPR50 mice showed early-onset memory deficits as 
revealed by the Y-maze and novel object recognition tests at 5 months of age (Figure 6), 
when intracellular tau accumulation is not evident yet. At this age, although an 
increase in sarkosyl-insoluble tau and reduction in calbindin were speculated (Figures 4 
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and 7), I found MT-related protein expression and MT dynamics were already altered 
even at an earlier age (3 or 4 months of age) (Figures 7 and 8). Acetylated tubulin is a 
known marker of MT stability (Black et al., 1989), and the increase in acetylated 
tubulin and total tubulin may reflect an alteration in MT turnover in TPR50 mice. 
Although the mechanism for the increase in KHC expression is unknown, it may reflect 
a compensatory mechanism in response to axonal dysfunction because KHC is linked to 
axonal transport (Hurd and Saxton, 1996; Stokin et al., 2005; Henthorn et al., 2011). 
Alternatively, KHC may be upregulated in the presence of greater numbers of kinesin 
epitopes associated with MT hyperdynamics. Indeed, abnormality of MT dynamics in 
TPR50 mice was observed in this study with 2H labeling (Figure 8). Age-dependent MT 
hyperdynamism was also reported in another tau transgenic mouse and in an ALS 
mouse model (Fanara et al., 2007; Barten et al., 2012), suggesting that MT 
hyperdynamism may be a common feature of cytoskeletal dysfunction in 
neurodegenerative disease models. In addition, TPR50 mice impaired retrograde axonal 
transport in the septohippocampal pathway at 5 months of age (Figure 9). Belarbi and 
colleagues recently reported that THY-tau22 mice, a tau Tg mouse with G272V and 
P301S mutations, exhibited impaired retrograde axonal transport in the 
septohippocampal pathway coincident with tau pathology and loss of ChAT-positive 
cholinergic neurons in the medial septum (Belarbi et al., 2009, 2011). In contrast, 
TPR50 mice showed impaired axonal transport prior to intracellular tau accumulation 
and before neurodegeneration as assessed by the expressions of neuronal/synaptic 
markers in the hippocampus. Neither intracellular tau accumulation nor drastic 
neurodegeneration was observed in the septal area at this age (Supplementary Figure 
7). Thus, axonal dysfunction in the hippocampus precedes tau pathology and neuronal 
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death in TPR50 mice but correlates with the onset of cognitive dysfunction.  
The triggers for axonal dysfunction in TPR50 mice remain unclear. As shown in Figure 
4A, slight amounts of sarkosyl-insoluble tau were already observed even at 3 months of 
age and they may significantly affect neuronal function. On the other hand, it has been 
recently emphasized that soluble tau plays an important role in neuronal dysfunction 
(Wittmann et al., 2001; SantaCruz et al., 2005), and my previous study found that a 
decrease in soluble phosphorylated tau rescued cognitive impairments in an AD mouse 
model (Onishi et al., 2011). These observations support the idea that an increase in 
soluble and phosphorylated tau may perturb neuronal function in TPR50 mice. Taken 
together, my results strongly suggest that overexpression of soluble tau accelerates MT 
turnover, and this MT hyperdynamicity results in axonal dysfunction and cognitive 
impairments in TPR50 mice. This idea is also supported by reports showing therapeutic 
effects of MT-stabilizing compounds such as paclitaxel and epothilone D on axonal 
dysfunction and behavioral anomalies in tau Tg mice (Zhang et al., 2005; Brunden et al., 
2010; Zhang et al., 2012), suggesting that regulation of tau phosphorylation and 
stabilization or protection of axon could be a good therapeutic approach.  
In this study, I described TPR50 mice, a novel P301S tau Tg mouse model of tauopathy. 
These mice demonstrate not only age-dependent abnormalities in tau phosphorylation, 
insoluble tau accumulation, altered expression of neuronal proteins, and age-dependent 
motor dysfunction described in previous tauopathy models but also early-onset MT 
hyperdynamicity and cognitive impairments. In addition to studies of FTLD progression 
and pathogenesis, these mice may be useful for identifying and validating anti-tau 
therapies to treat neurodegenerative diseases. 
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Figures 
 
Figure 1. Human tau expression, motor deficits, and decreased body weight in male 
TPR50 mice. Expression of human tau in WT (A, left) and TPR50 (A, right) mice was 
immunohistochemically examined with a human tau antibody (male, 9 months of age). 
TPR50 mice showed age-dependent motor deficits; 8.5-month-old TPR50 mice (B, right) 
but not 5-month-old TPR50 mice (B, left) clasped their hind limbs when lifted by the tail. 
Comparison of body weight between WT and TPR50 (Tg) mice at 5, 7, and 9.5 months of 
age (C). The body weight of TPR50 mice was less than that of WT mice. Data are 
expressed as mean ± SEM. ** p ≤ 0.01 by Welch’s test or Student’s t-test, n = 6.  
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Figure 2. Expression of phosphorylated human tau by TPR50 mice. Western blots 
probing tau expression in the hippocampal soluble fraction from 9.5-month-old TPR50 
mice. Total tau and tau phosphorylated at T181 (detected with AT270), S202/T205 
(detected with AT8), S214, S262, and S396 were examined by immunoblot analysis in 
TPR50 (Tg) and WT mice (A). Comparison of tau expression between TPR50 and WT 
mice (B‒H). Data are expressed as mean ± SEM. ** p ≤ 0.01 by Student’s t-test, n = 5 or 
6. n.s., not significant.  
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Figure 3. Age-dependent change in tau phosphorylation in TPR50 mice. Tau expression 
in the soluble fraction from the hippocampus of TPR50 (Tg) and WT mice at 3, 6, and 9 
months of age were examined by Western blotting using antibodies against 
pS202/T205-tau (detected with AT8), pS262-tau, pS396-tau, and total tau (A) and 
analyzed by densitometry (B‒E). Data are expressed as mean ± SEM. ** p ≤ 0.01 by 
Student’s t-test, n = 5.  
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Figure 4. Age-dependent change in sarkosyl-insoluble tau in TPR50 mice. 
Sarkosyl-insoluble tau levels in the hippocampus of TPR50 (Tg) and WT mice at 3, 6, 
and 9 months of age were examined by Western blotting using antibodies against 
pS202/T205-tau (detected with AT8), pS262-tau, pS396-tau, and total tau (A) and 
analyzed by densitometry (B‒E). Data are expressed as mean ± SEM. ** p ≤ 0.01 by 
Student’s t-test, n = 5. n.s., not significant.  
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Figure 5. Intracellular tau accumulation in TPR50 mice. Hippocampal sections were 
examined by immunohistochemistry using human tau antibody (HT7). A, D: 
9-month-old WT mice, B, E: 6-month-old TPR50 mice, C, F: 9-month-old TPR50 mice. 
Bar = 1 mm (A‒C); 100 μm (D‒F).  
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Figure 6. Cognitive deficits in 5-month-old TPR50 mice. Working memory and cognitive 
function were assessed by the Y-maze test and the novel object recognition test. In the 
Y-maze test, %alternation was significantly reduced in Tg mice during a 5-minute 
exploration (A). In the novel object recognition test, exploration of a novel object was 
evaluated during the retention phase, 24 h after acquisition. Novel object recognition 
performance is shown as exploration time and novel object preference ratio (B). Data 
are expressed as mean ± SEM. * p ≤ 0.05 by Student’s t-test, n = 10. n.s., not significant. 
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Figure 7. Expression of α–tubulin, acetylated tubulin, kinesin heavy chain (KHC), 
calbindin, synaptophysin, and β‒actin in TPR50 mice. Hippocampal expression of these 
proteins in TPR50 (Tg) and WT mice at 3, 6, and 9 months of age were examined by 
Western blotting (A) and quantitative densitometry (B‒G). Data are expressed as mean 
± SEM. * p ≤ 0.05, ** p ≤ 0.01 by Student’s t-test, n = 5. n.s., not significant.  
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Figure 8. MThyperdynamics in TPR50 mice. In vivo MT dynamics measured in the 
cerebral cortex (A and D), hippocampus (B and E), and cerebellum (C and F) of TPR50 
(Tg) and WT mice at 4 (A‒C) and 7 (D‒F) months of age. Data are expressed as mean ± 
SEM. * p ≤ 0.05, ** p ≤ 0.01 by Student’s t-test, n = 3. n.s., not significant.  
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Figure 9. Impaired septohippocampal retrograde transport in TPR50. The retrograde 
axonal tracer Fluoro-Gold was injected into the right hippocampus of 5-month-old 
TPR50 (Tg) and WT mice. Three days after injection, labeled neurons in the medial 
septum were surveyed in WT (A) and Tg (B) mice and counted (C). Data was expressed 
as mean ± SEM. *p ≤ 0.05 by Student’s t-test, n = 8. Bar = 500 μm 
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Supplementary Information 
 
Supplementary Figure 1. Generation of the TPR50 mouse. (A) The open reading frame 
(ORF) of the mouse prion gene in the BAC vector (RPCI-23-401J24) was replaced with 
the human 4R2N tau gene harboring the P301S mutation and a selection cassette 
flanked by loxP sequences by ET recombination. Tg mice were generated by 
microinjection of the vector into oocytes harvested from BDF1 mice. (B) Expression of 
human tau in the 7 lines obtained (TPR16, 50, 56, 72, 82, 96, and 100). Human tau was 
measured by ELISA. Data was expressed as mean ± SEM, n = 3.  
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Supplementary Figure 2 Kaplan‒Meier curve of time to natural death or required 
euthanasia of male TPR50 (Tg) and WT mice.  
Data are expressed as %survival, n = 24/group.  
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Supplementary Figure 3. RAB-RIPA-FA extraction of tau from the hippocampus of 
TPR50 mice at 3, 6, and 9 months of age. Each fraction was examined by Western 
blotting using antibodies against pS202/T205-tau (detected with AT8) and total tau (A) 
and analyzed by densitometry (B). Data are expressed as the scatter dot plot and mean 
± SEM, n = 5. 
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Supplementary Figure 4. Motor phenotype assessed by the rotarod in young TPR50 
mice. TPR50 mice and WT mice at 5 months of age were subjected to the rotarod test, 
and motor function was expressed as latency to fall off the apparatus. Data are 
expressed as mean ± SEM and statistically analyzed by Student’s t-test, n = 8. n.s., not 
significant.  
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Supplementary Figure 5. Experimental scheme for evaluation of retrograde axonal 
transport in the septohippocampal pathway. Fluoro-Gold is injected into the 
hippocampus, the target of septal cholinergic neuron projections (left). The dye was 
diffused in the ipsilateral site of injection while the contralateral site was intact. Cells 
labeled by the dye transported to the septum in a retrograde manner were detected in 
the septum (right). MS, medial septal nucleus.  
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Supplementary Figure 6. Tangle-like pathology in 9-month-old TPR50 mice examined 
by Bielschowsky sliver staining. (A) Sagittal section, (B) coronal section of hippocampus. 
Bar = 100 μm 
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Supplementary Figure 7. Histological analysis of 5-month-old TPR50 mice. Septal 
sections were examined by immunohistochemistry using a human tau antibody (HT7) 
(A‒D) and HE staining (E and F). C and D are magnified regions of A and B, respectively. 
Hippocampal sections were examined by immunohistochemistry using antibodies for 
synaptophysin (G and H). A, C, E, and G: 5-month-old WT mice, B, D, F, and H: 
5-month-old TPR50 mice. Bar = 1 mm (A, B, E, and F); 100 μm (C, D, E, and F).  
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Part II 
A Novel Glycogen Synthase Kinase-3 Inhibitor 
2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole 
(MMBO) Decreases Tau Phosphorylation and Ameliorates Cognitive Deficits in a 
Transgenic Model of Alzheimer’s Disease  
62 
 
Abstract 
 
AD is a neurodegenerative disorder leading to a progressive loss of cognitive function 
and is pathologically characterized by senile plaques and NFTs. GSK-3 is involved in 
AD pathogenesis. GSK-3 is reported not only to phosphorylate tau, a major component 
of NFTs, but also to regulate the production of Aβ, which is deposited in senile plaques. 
Therefore, pharmacological inhibition of GSK-3 is considered an attractive therapeutic 
approach. Here, I report the pharmacological effects of a novel GSK-3 inhibitor, MMBO, 
which displays high selectivity for GSK-3 and brain penetration following oral 
administration. MMBO inhibited tau phosphorylation in primary neural cell culture 
and also in normal mouse brain. When administered to a transgenic mouse model of AD, 
MMBO significantly decreased hippocampal tau phosphorylation at GSK-3 sites. 
Additionally, chronic MMBO administration suppressed tau pathology as assessed by 
AT8-immunoreactivity without affecting Aβ pathology. Finally, in behavioral 
assessments, MMBO significantly improved memory and cognitive deficits in the 
Y-maze and in novel object recognition tests in the transgenic AD mouse model. These 
results indicate that pharmacological GSK-3 inhibition ameliorates behavioral 
dysfunction with suppression of tau phosphorylation in an AD mouse model, and that 
MMBO might be beneficial for AD treatment.  
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Introduction 
 
AD is a neurodegenerative disorder characterized by a progressive deterioration in 
cognitive function and memory and has two pathological hallmark lesions: senile 
plaques and NFTs. These pathological features are comprised of the small peptide, Aβ 
and the MT-associated protein, tau, which is hyperphosphorylated at specific sites 
(Grundke-Iqbal et al., 1986; Friedhoff et al., 2000). Hyperphosphorylation of tau is 
thought to result in its pathological aggregation with a contribution from several 
kinases such as GSK-3β (Sperber et al., 1995) and cyclin-dependent kinase 5 (CDK5) 
(Cruz and Tsai, 2004). 
GSK-3β is reported to phosphorylate tau and affect MTrearrangement in vitro 
(Lovestone et al., 1996; Wagner et al., 1996) and also to be associated with the formation 
of tau oligomeric fibrils (Sato et al., 2002; Ishizawa et al., 2003; Noble et al., 2003)and 
NFTs in AD (Pei et al., 1997, 1999). In addition, overexpression or activation of GSK-3β 
in mice induces AD-like symptoms such as tau hyperphosphorylation and cognitive 
deficits (Lucas et al., 2001; Hernández et al., 2002; Engel et al., 2006; Wang et al., 2008). 
These phenotypes are completely reversed after silencing of a GSK-3β transgene with 
the Tet-off system (Engel et al., 2006). These reports indicate that inhibition of GSK-3β 
can be a potent therapeutic approach for AD. In fact, some reports show that inhibition 
of GSK-3β with small molecules including lithium, a medication for bipolar disorder, 
decreases tau phosphorylation and improves neuronal abnormalities such as motor 
deficits in JNPL3 mice (Noble et al., 2005; Le Corre et al., 2006).  
Other reports imply that GSK-3α and β may also affect Aβ production. GSK-3α 
regulates Aβ production via γ–secretase (Phiel et al., 2003), and lithium reduces Aβ 
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plaque pathology in APP Tg mice (Su et al., 2004). Moreover, dominant-negative 
(DN)-GSK-3β Tg mice crossed with APP Tg mice show reduced APP phosphorylation 
and Aβ plaque pathology (Rockenstein et al., 2007). These results indicate that GSK-3 
inhibition might represent a beneficial strategy for lowering Aβ as well as for inhibiting 
tau phosphorylation. 
So far, lithium has been widely used as a GSK-3 inhibitor in many pharmacological 
studies. Lithium inhibits GSK-3β activity both directly (Klein and Melton, 1996; Phiel 
and Klein, 2001) and indirectly (Chalecka-Franaszek and Chuang, 1999; Zhang et al., 
2003). However, lithium is known to inhibit not only GSK-3 but also other important 
kinases such as casein kinase 2 (CK2), mitogen-activated protein kinase activated 
protein kinase 2 (MAPKAP-K2) and p38-regulated/activated kinase (PRAK) (Davies et 
al., 2000). Therefore, I conducted this study in order to clarify potential of GSK-3 as a 
therapeutic target for neurodegenerative diseases.  
Here, I report a further investigation into the pharmacological inhibition of GSK-3 
using a novel, selective inhibitor in 3xTg-AD mice. The inhibitor is highly selective for 
GSK-3, and also orally effective in vivo (Saitoh et al., 2009a and 2009b). Triple Tg-AD 
mice express human mutant APPswe, PS1M146V and tauP301L and develop both Aβ plaques 
and NFTs in an age- and region-dependent manner (Oddo et al., 2003). In addition, they 
also suffer age-dependent deficits in cognition and learning behavior (Billings et al., 
2005; Clinton et al., 2007; Gimenez-Llort et al., 2007). Therefore, using these mice as a 
model of AD, we examined the putative therapeutic effects of a selective GSK-3 
inhibitor on AD-like pathology and associated behaviors.  
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Materials and Methods 
 
Animals 
The 3xTg-AD mice, originallydeveloped by Oddo and colleagues (2003), were bred in 
our laboratories and were used in this study. The 3xTg-AD mice were derived by 
co-microinjected human APP with the Swedish mutation (KM670/671NL) and human 
tau with the P301L mutation (both regulated under the Thy1.2 promoter) into 
single-cell embryos harvested from homozygous mutant PS1M146V knockin (PS1-KI) 
mice. The background of the PS1-KI is a hybrid 129/C57BL6 used as a NonTg control. 
The JNPL3 and wild type control mice were purchased from Taconic (Hudson, NY). 
JNPL3 mice express human tau with a P301L mutation under the mouse prion 
promoter (MoPrP) and their background is C57BL/DBA/SW (Lewis et al., 2000). Mice 
were housed in groups on 12 h light/dark cycles and were provided ad libitum access to 
food and water. All animals were maintained and sacrificed according to the guidelines 
of the Takeda Experimental Animal Care and Use Committee.  
 
Chemical treatment 
A GSK-3 inhibitor, 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)- 
1,3,4-oxadiazole (MMBO),was synthesized in our laboratories (Saitoh et al., 2009a). The 
compound was dissolved in DMSO at a concentration of 30 mM and was applied to cells 
after dilution with medium at the indicated concentrations. In the in vivo experiments, 
MMBO was reconstituted in 0.5% methylcellulose and administered orally at the 
indicated doses. To evaluate tau pathology, MMBO was administered for22 days to 
13-month-old 3xTg-AD mice (p.o., b.i.d.). To assess APP/Aβ metabolism, MMBO was 
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administered for 33 days to 11-month-old 3xTg-AD mice (p.o., b.i.d.).Behavioral tests 
were also performed in these animals. At a treatment time of 17 days and 25 days, 
Y-maze tests and novel object recognition tests were performed, respectively.  
 
Kinase assay 
Human GSK-3α and GSK-3β were purchased from Millipore Corp. (Bedford, MA). The 
kinase assay was performed according to methods previously reported (Uno et al., 2009). 
Briefly, the reaction was conducted in 25 mM HEPES (pH 7.5), 10 mM magnesium 
acetate, 1 mM dithiothreitol, and 0.01% BSA. Compounds were dissolved in DMSO and 
then applied at the indicated doses in each reaction. The final amount of enzyme and 
substrate were optimized to the following: 40 ng/well of enzyme and 400 ng/well of 
GSK-3 substrate peptide (Millipore Corp.). All kinase reactions were started by addition 
of the ATP solution (final concentration 500 nM), and incubations occurred for 45 
minutes at room temperature. The reactions were terminated by the Kinase-Glo 
reagent containing EDTA (50 μL/well, Promega Corp., Madison, WI, USA). Ten minutes 
after the addition of the Kinase-Glo reagent, luminescence was measured.  
 
Antibodies 
The following antibodies were used in this study: AT8 (Innogenetics, Ghent, Belgium), 
Ab-3 (Thermo Fisher Scientific, Fremont, CA, USA), pS199-tau (Invitrogen, Carlsbad, 
CA, USA), pS214-tau (Invitrogen), HT7 (Innogenetics), pT205-tau (Invitrogen), 
pS396-tau (Invitrogen), AT270 (Innogenetics), AT180 (Innogenetics) and -actin (Sigma, 
St. Louis, MO). Antibodies for Aβ used in this study (BNT77, BA27, and BC05) have 
been previously described (Asami-Odaka et al., 1995).  
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Rat primary culture and tau phosphorylation inhibition assay 
Primary cortical neurons were prepared from E17 SD rat embryos (Japan Slc, 
Shizuoka, Japan) using a papain-containing nerve cell dispersion kit (Sumitomo 
Bakelite, Akita, Japan). Isolated cells were suspended in nerve cell culture medium 
(Sumitomo Bakelite). The cells were seeded on poly-D-lysine/laminin coated plates (BD, 
Franklin Lakes, NJ, USA) under 5% CO2 at 37ºC for 4 DIV to estimate tau 
phosphorylation. In the assay, cells were treated with MMBO at the indicated 
concentrations for 2 hours, then fixed with 4% paraformaldehyde (Wako, Osaka, Japan) 
for 30 minutes at room temperature, and finally treated for 1 hour with 1.5% BSA and 
0.1% TritonX-100 in PBS at room temperature. Neurons were then immunostained with 
primary antibodies against phosphorylated tau (AT8, 1: 200 dilution) or total tau (Ab-3, 
1: 500 dilution) and then labeled with Alexa-conjugated secondary antibodies 
(Invitrogen). Images were captured using a TE2000-U (Nikon, Tokyo, Japan).  
 
Aβ measurement by ELISA 
Hippocampi were isolated from animals and immediately frozen on dry ice and stored 
at –80ºC until assay. Samples were homogenized in ice-cold Tris-extraction buffer (50 
mM Tris-HCl, pH 7.2, 200 mM sodium chloride, 2% protease-free bovine serum albumin, 
and 0.01% sodium merthiolate) containing protease inhibitor cocktails (Roche, Basel, 
Switzerland). After centrifugation at 15,000 g for 15 minutes, the supernatants were 
subjected to two-site sandwich ELISA to measure amounts of soluble Aβ. For 
assessment of insoluble Aβ, the pellets were homogenized in guanidine extraction buffer 
(5 M guanidine, 50 mM Tris-HCl (pH 7.2)) and centrifuged at 15,000 g for 15 minutes. 
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The supernatants were diluted with 19-fold Tris-extraction buffer and subjected to 
ELISA. Aβ40 or Aβ42 was quantified by two-site sandwich ELISA using BNT77, which 
recognizes Aβ11-16, as a capture antibody and BA27-HRP or BC05-HRP as a detector 
antibody, respectively, as described previously (Asami-Odaka et al., 1995). 
 
Western blotting 
Hippocampi isolated from mice were homogenized in RIPA extraction buffer (50 mM 
Tris-HCl, 5 mM EDTA, 1 mM EGTA, 100 mM NaCl, 1% NP-40 and 2.5% sodium 
deoxycholate, pH7.5) supplemented with protease inhibitors (1.37 mg/L pepstatin A, 25 
KIU/mL aprotinin, 1 nM microcystin LR, 1 nM MG115, 40 nM leupeptin and 100 nM 
4-(2-aminoethyl)benzenesulfonyl fluoride HCl) and phosphatase inhibitors (30 mM NaF, 
sodium diphosphate, 2 nM sodium orthovanadate). The homogenate was centrifuged at 
10,000 g for 10 minutes and the supernatant was taken as the soluble fraction. Protein 
concentration was determined using the BCA assay kit (Pierce, Rockford, IL). Equal 
amounts of protein (1-10 μg depending on the protein of interest) were separated by 
SDS-PAGE on a 10% polyacrylamide gel, then electrophoretically transferred to 0.45 μm 
poly-vinylidene difluoride membranes (Millipore) and blocked for 1 hour in BlockAce 
(DS Pharma Biomedical, Osaka, Japan). After blocking, membranes were probed with 
primary antibodies followed by labeling with horseradish peroxidase-coupled secondary 
antibodies (Amersham, Piscataway, NJ), and then visualized by a chemiluminescence 
reagent (Immunostar; Wako) using a LAS1000 imaging system (Fujifilm, Tokyo, Japan). 
Quantitative densitometric analyses were performed with Image Gauge (Fujifilm). 
Values presented are derived from densitometry arbitrary units (AU).   
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Statistical analysis 
Data are expressed as mean ± SEM and were analyzed by the one-tailed Williams’ test, 
and p = 0.025 or lower was considered significant. For comparisons between 
vehicle-treated WT mice and vehicle-treated Tg mice, Student’s t-tests were performed 
using p = 0.05 or lower as a significant level. Student’s t-tests were also used for 
comparisons in the novel object recognition test. Analyses were performed with SAS 
system 8 (SAS Institute, Cary, NC, USA) 
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Results 
 
MMBO, a novel GSK-3 inhibitor, decreased tau phosphorylation in vitro and in vivo 
In this study, I used a novel GSK-3 inhibitor, MMBO. The chemical structure of MMBO 
is shown in Figure 10. This compound displays high selectivity for GSK-3 out of various 
kinases such as cyclin-dependent kinase 5 (CDK5), extracellular signal-regulated 
kinase 1 (ERK1), and Jun N-terminal kinase (JNK), although selectivity for GSK-3α vs. 
GSK-3β is unknown (Saitoh et al., 2009b). Therefore, we first evaluated the inhibitory 
activity of MMBO on GSK-3α/β. As shown in Table 1, MMBO inhibited both GSK-3α and 
β to a similar extent with an IC50 of 37 and 53 nM, respectively. Lithium, a well-known 
GSK-3 inhibitor, also inhibited both subtypes, but its inhibitory activities were much 
weaker compared to MMBO.  
To examine whether MMBO decreases tau phosphorylation in neural cells, rat primary 
neural cell cultures were treated with MMBO. The amount of phosphorylated tau was 
assessed by immunostaining (Figures 11A-I) or Western blotting (Figures 11J and K) 
with AT8 antibody, which recognizes tau phosphorylated at S202 and T205. While 
DMSO-treated neurons showed AT8-positive immunoreactivity identical to total tau 
stained with Ab-3 (Figures 11A-C), MMBO-treated cells showed a reduction of AT8 
immunostaining without any changes in total tau (Figures 11D-I). Results of Western 
blotting and quantitative analyses supported these observations (Figures 11J and K).  
Next, I examined the brain penetration and tau phosphorylation inhibitory activity of 
MMBO in vivo. MMBO was administered to C57BL/6N mice and its brain concentration 
was measured. Area under the curve (AUC) concentration values from 0-24 hours after 
administration in the brain and plasma were 734.2 ng·h/g and 457.4 ng·h/mL, 
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respectively, when orally dosed at 3 mg/kg, indicating that MMBO is able to penetrate 
the brain (Table 2A). Time course profiles of concentrations in brain and plasma were 
similar, and maximum concentrations were seen 30 minutes after administration (Table 
2B). Tau phosphorylation in the hippocampus was assessed by pT205-tau and total tau 
antibodies (Figures 12A and B). Tau phosphorylation in MMBO-treated mice was 
decreased 30 minutes after administration, and then returned to baseline level by 4 
hours. The time course profile of tau phosphorylation reduction was well correlated with 
drug levels.  
 
Effects of MMBO on tau phosphorylation and pathology in 3xTg-AD mice 
To evaluate the effects of MMBO on tau phosphorylation in an AD animal model, we 
administered the drug to 3xTg-AD mice. Triple Tg-AD mice reveal AD-like tau 
pathology and memory impairments without the motor deficits seen in other tau 
transgenic mice, such as JNPL3 mice (Lewis et al., 2000). Therefore, 3xTg-AD mice 
were thought to be the most suitable for the evaluation of MMBO. In addition, human 
tau expression in 3xTg-AD mice varied less compared to JNPL3 mice (Supplementary 
Figure 8), suggesting that 3xTg-AD mice are useful for pharmacological studies of tau 
pathology.  
MMBO was administered orally to the 3xTg-AD mice at doses of 3 and 10 mg/kg. Tau 
phosphorylation at T181, S199, T205, S202/T205, T231, and S396, residues reported to 
be GSK-3β-sensitive sites, were significantly reduced by MMBO in a dose-dependent 
manner, while total tau levels were comparable among all groups (Figure 13). Tau 
phosphorylation at S214 was not inhibited by MMBO (Figures 13A and F), indicating 
that this phosphorylation site might not be affected directly by GSK-3, as reported in 
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previous in vitro studies (Liu et al., 2002; Wang et al., 2007).  
To assess the effects of MMBO on tau pathology, MMBO was administered to 
13-month-old 3xTg-AD mice for 3 weeks. Consistent with a previous report mentioning 
that AT8-reactive neurons become apparent between 12 to 15 months of age (Oddo et al., 
2003), AT8-positive phosphorylated tau and HT7-positive total human tau both 
pathologically accumulated in the CA1 of 3xTg-AD mice (Figures 14A, D, G and J). The 
AT8-positive pathology was reduced by treatment with MMBO in a dose-dependent 
manner (Figures 14A-F). HT7-positive total tau in MMBO-treated animals only showed 
a trend towards reduction when compared to vehicle-treated mice (Figures 14G-L). 
 
Effects of MMBO on APP metabolism in 3xTg-AD mice  
As described above, previous studies also show that GSK-3 regulates Aβ production. 
Therefore, I examined whether MMBO affects APP metabolism and Aβ pathology in 
3xTg-AD mice. MMBO was administered to 11-month-old 3xTg-AD mice (at which time 
Aβ pathology is considered to be forming) for 5 weeks. Subsequently, Tris-soluble and 
insoluble Aβ levels in the hippocampus were measured. MMBO at 1 and 3 mg/kg did not 
change Aβ levels (Figures 15A and B). Aβ deposits in hippocampi evaluated by 
immunohistochemistry using the Aβ antibody were also not different between vehicle- 
and MMBO-treated animals (Figure 15C). Since previous studies suggested that GSK-3 
regulates phosphorylation-dependent Aβ production (Aplin et al., 1996; Ryder et al., 
2003; Su et al., 2004; Rockenstein et al., 2007), APP phosphorylation at Thr688 was 
examined in the hippocampi of MMBO-treated mice. However, APP phosphorylation 
was not affected by MMBO treatment (Figure 15D).  
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Effects of MMBO on cognitive behavior in 3xTg-AD mice 
Finally, the effect of MMBO on cognitive behavior was assessed. MMBO was 
chronically administered to 11-month-old 3xTg-AD mice. Subsequently, Y-maze tests 
were performed. Spontaneous alternation in the Y-maze primarily depends on 
hippocampal function and is often used to evaluate short-term memory. Triple Tg-AD 
mice showed impaired spontaneous alternation performance compared with 
vehicle-treated WT mice (p ≤ 0.01) (Figure 16A). Mice treated with MMBO for 17 days 
increased their spontaneous alternation in a dose-dependent manner (p ≤ 0.025). Total 
arm entries were significantly decreased in Tg mice compared to the WT group, but 
were comparable between vehicle and MMBO treatment groups (Figure 16B). 
Thereafter, cognitive function was assessed in the novel object recognition test 8 days 
after the Y-maze (on the 25th day of treatment). During the acquisition phase, all mice 
explored both objects (objects A and A*) comparably (data not shown). After a 5-hour 
delay, while the vehicle-treated WT mice showed significant exploration of the novel 
object (object B) (p ≤ 0.001), the 3xTg-AD mice treated with vehicle were impaired in 
their recognition of the novel object as shown in Figure 17. In contrast, MMBO 
significantly increased the frequency of exploration of the novel object and the 
recognition index (p ≤ 0.05). These results indicate that MMBO improved both memory 
and cognitive function in 3xTg-AD mice.  
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Discussion 
 
In this study, I examined the therapeutic effects of GSK-3 inhibition with a novel 
compound, MMBO, which displays good selectivity for GSK-3, bioavailability, and brain 
permeability (Saitoh et al., 2009b). MMBO decreased tau phosphorylation both in vitro 
and in vivo. In 3xTg-AD mice, MMBO significantly reduced tau phosphorylation in a 
dose-dependent manner at residues regulated by GSK-3 (Figure 13).  
Previous studies have shown that GSK-3 inhibitors such as lithium and AR-A014418 
decrease tau phosphorylation in vivo and suppress tau pathology in JNPL3 mice (Pérez 
et al., 2003; Noble et al., 2005). MMBO displayed greater in vivo efficacy than lithium 
and AR-A014418 as evaluated in the cold-water stress (CWS) model (data not shown). 
MMBO also suppressed AT8-positive (phosphorylated tau) pathology and ameliorated 
cognitive behavioral deficits in 3xTg-AD mice in spite of insignificant changes in 
HT7-positive (total tau) pathology. This result suggests that MMBO might not 
drastically suppress tau accumulation but might affect the phosphorylation of 
intracellular tau, and the effect on intracellular soluble tau might produce the 
behavioral improvements observed. A similar discovery was reported by Oddo and 
colleagues (2006), who found that Aβ immunotherapy in 3xTg-AD mice ameliorated 
cognitive impairment when reducing both soluble Aβ and soluble tau, but not insoluble 
tau. Additionally, some recent reports have shown that soluble tau plays an important 
role in impaired neural function. In APP Tg mice, soluble tau mediated the 
excitotoxicity induced by Aβ (Palop et al., 2007; Roberson et al., 2007). In rTg4510 mice, 
memory deficits and neuronal cell loss were independent of NFTs (Santacruz et al., 
2005). Tau-overexpressing flies also showed progressive neurodegeneration in the 
75 
 
absence of NFTs (Wittmann et al., 2001). Consistent with my observations, these 
reports could indicate that protection from toxicity induced by soluble tau represents a 
therapeutic strategy for neurodegenerative diseases including AD, although the toxicity 
of soluble tau has not been explicitly demonstrated. Additionally, the fact that antibody 
responders following Aβ vaccination show a decrease in soluble tau levels in the 
cerebrospinal fluid (CSF) would seem to provide further evidence of the importance of 
soluble tau in cognitive function (Gilman et al., 2005).  
Recently, Caccamo and colleagues reported the effects of lithium in 3xTg-AD mice 
(2007). Lithium treatment decreased tau phosphorylation as measured by Western 
blotting and immunohistochemistry, similar to my results with MMBO, but did not 
rescue working memory impairments as assessed by the T-maze test. They speculated 
that a decrease in both soluble Aβ and soluble tau might be necessary to improve 
working memory impairments in 3xTg-AD mice, as was found with Aβ immunotherapy 
(Oddo et al., 2006). Comparatively, MMBO was able to ameliorate behavioral deficits in 
3xTg-AD mice (Figure 17). The reason why MMBO but not lithium improved working 
memory in 3xTg-AD mice might be based on several differences in experimental 
procedures and conditions between these studies. One of the differences involves the 
particular behavioral tasks assessed. In the previous study, the effects of lithium were 
evaluated in the T-maze, while, as I show here, MMBO was effective in the Y-maze and 
novel object recognition tests. Although alternation performance is commonly used in 
both the T-maze and Y-maze as an index of memory, the Y-maze might be more sensitive 
for the evaluation of GSK-3β inhibitors. Another difference might relate to the 
inhibitory activity and specificity of the compounds. MMBO has more specific activity 
against GSK-3 and greater in vivo efficacy compared to lithium. In addition, the ages of 
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the 3xTg-AD mice used also differed, as Caccamo et al. evaluated 15-month-old mice 
while I used somewhat younger animals. In this case, there might be a specific, suitable 
age for behavioral evaluation.  
AD is characterized by the presence of Aβ plaques in addition to tauopathy, and GSK-3 
is reported to also regulate Aβ production. Although previous reports suggested a 
beneficial effect of GSK-3 inhibition on lowering Aβ (as mentioned above), in the current 
study, pharmacological inhibition of GSK-3 with MMBO did not significantly change Aβ 
levels or Aβ plaque formation (Figures 15A-C). Additionally, APP phosphorylation was 
not affected by MMBO treatment (Figure 15D). In a separate series of experiments, 
acutely administered MMBO did not decrease APP phosphorylation or soluble Aβ40 or 
Aβ42 in C57BL/6N mice, although slight Aβ-lowering effects separate from cytotoxicity 
could be observed in vitro (data not shown). Taken together, the therapeutic effects of 
MMBO as seen in behavioral tests might be produced via the inhibition of tau 
phosphorylation but not via the lowering of Aβ. However, further studies will be 
required to produce a definitive answer. 
The current study shows that administration of MMBO, which is a highly selective and 
potent GSK-3 inhibitor, leads to cognitive improvement in an AD mouse model. 
Previous reports have shown that lithium ameliorates behavioral deficits in animal 
models of cognitive decline, but lithium does not display a strong inhibitory activity of or 
specificity for GSK-3 compared with MMBO. Additionally, no obvious clinical effects of 
lithium were observed in AD patients (Hampel et al., 2009). In this human study, GSK-3 
activity in lymphocytes was not affected by lithium, and therefore it is possible the 
administered dose might not have been sufficient for GSK-3 inhibition. Thus, the use of 
a stronger or more selective GSK-3 inhibitor like MMBO may be more advantageous as 
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an AD therapy. In conclusion, pharmacological GSK-3 inhibition and the resultant 
decrease in tau phosphorylation may represent a valid therapeutic strategy for AD.  
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Tables and Figures 
 
Table 1. Comparison of MMBO and lithium on inhibition of GSK-3α and β activity.  
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GSK-3α GSK-3β
MMBO 37 53
Lithium 41 x 10
6
71 x 10
6 [nM]
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Table 2. Single-dose pharmacokinetic profiles of MMBO in mice following oral (3 mg/kg) 
administration.  
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A 
B 
Brain Plasma
Cmax (ng/g or ng/mL) 579.8 353.9
Tmax (h) 0.50 0.50
AUC0-24h (ng･h/g or ng･h/mL) 734.2 457.4
MRT (h) 1.09 1.13
Brain [ng/g] Plasma [ng/mL]
Time (h)
0.25 409.4 (85.6) 246.7 (49.2)
0.5 579.8 (50.3) 353.9 (29.5)
1 334.6 (93.4) 201.5 (64.7)
2 80.6 (22.5) 58.2 (18.9)
4 14.2 (12.3) 7.2 (6.3)
8 0 0.3 (0.6)
24 0 0
Mean (S.D.)
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Figure 10. Chemical structure of MMBO 
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Figure11. Effects of MMBO on tau phosphorylation in rat primary neurons detected by 
AT8. Rat primary cortical neurons at DIV4 were treated with MMBO at 10 and 30 μM 
for 2 hours. MMBO inhibited intracellular tau phosphorylation (arrowheads) in a 
concentration-dependent manner. Phosphorylated tau (A, D, and G) and total tau (B, E, 
and H) were immunostained by AT8 and Ab-3, respectively. Merged images are shown 
in C, F, and I. Bar = 20 μm. Western blotting with AT8 and Ab-3 was also performed (J), 
and % change from DMSO treated cells was quantified (K).  
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Figure12. Effects of MMBO on tau phosphorylation in vivo. Phosphorylated tau in the 
hippocampus was evaluated at the indicated time (0.5, 1, 2, 4 and 8 hours) after the 
compound was administered at 10 mg/kg. Tau phosphorylation was analyzed by 
immunoblot (A) and measured quantitatively (B). Data were expressed as mean ± SEM, 
n = 5.  
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Figure13. Effects of MMBO on tau phosphorylation in 3xTg-AD mice. Vehicle or MMBO 
at 3 and 10 mg/kg were administered, and 30 minutes after administration 
phosphorylated tau (pT181-, pS199-, pT205-, pS202/pT205-, pS214-, pT231-, and 
pS396-tau) in the hippocampus was surveyed by Western blotting (A). Each 
phosphorylation ratio to total tau is shown as % change from vehicle-treated animals 
(B-H).  
Data were expressed as mean ± SEM (B-H) and analyzed by a one-tailed Williams’ test 
(vs. vehicle, # p ≤ 0.025), n = 10.  
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Figure14. Effects of MMBO on NFT-like tau pathology in CA1 pyramidal cells of 
3xTg-AD mice. Vehicle or MMBO (1 and 3 mg/kg, b.i.d.) was administered to 
13-month-old 3xTg-AD mice for 3 weeks. Hippocampi were immunohistochemically 
stained with AT8 (A-F) or HT-7 (G-L) and then counterstained with hematoxylin. D-F 
and J-L are magnified images of A-C and G-I, respectively. A, D, G, and J: vehicle, B, E, 
H, and K: 1 mg/kg, C, F, I, and L: 3 mg/kg. Bar = 300 μm.  
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Figure15. Effects of MMBO on APP metabolism and Aβ pathology. Vehicle or MMBO (1 
and 3 mg/kg, b.i.d.) was administered to 11-month-old 3xTg-AD mice for 1 month. 
Tris-soluble Aβ (A) and insoluble Aβ (B) in hippocampi were measured by ELISA. 
Hippocampi were also immunohistochemically stained with 6E10 (C). APP 
phosphorylation at T688 was assessed by Western blotting, and then analyzed 
quantitatively (D). Phosphorylation ratio to total APP is shown as % control. Data were 
expressed as mean ± SEM and analyzed by one-tailed Williams’ test (vs. vehicle, # p ≤ 
0.025), n = 7.  
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Figure16. Behavioral improvement in the Y-maze after MMBO administration in 
3xTg-AD mice. MMBO (1 and 3 mg/kg, b.i.d) or vehicle was administered for 16 days, 30 
minutes prior to the Y-maze test. Data are presented as % alternation rate (A) and total 
frequency of arm entries (B) during an 8-minute exploration. Data were expressed as 
mean ± SEM and analyzed statistically as follows: Student’s t-test (WT vs. Tg, * p ≤ 0.05, 
** p ≤ 0.01) and one-tailed Williams’ test (vs. vehicle, # p ≤ 0.025), n = 10.  
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Figure17. Behavioral improvement in a novel object recognition test after MMBO 
administration in 3xTg-AD mice. MMBO (1 and 3 mg/kg, b.i.d) or vehicle was 
administered for 24 days, 30 minutes prior to the acquisition phase. Exploration of a 
novel object was evaluated during retention phase, 5 hours after acquisition. Novel 
object recognition performance is shown as exploration frequency (A) or novel 
objectpreference ratio (B). Data were expressed as mean ± SEM and analyzed 
statistically as follows: Student’s t-test (novel object vs. familiar object or WT vs. Tg, * p 
≤ 0.05,** p ≤ 0.01, *** p ≤ 0.001) and one-tailed Williams’ test (vs. vehicle, # p ≤ 0.025), n 
= 10.  
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Supplementary Figure8. Amounts of tau in JNPL3 and 3xTg-AD mice. Total mouse and 
human tau, total human tau, and tau phosphorylated at T205, S396, T181, and 
S202/T205 were determined by immunoblot analysis (A). Quantitative comparisons of 
JNPL3 and 3xTg-AD mice are shown respectively in B-G. Data are expressed as scatter 
plots, n = 7 or 8.  
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General Discussion 
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In this study, I tried to examine the relationship between tau and etiology in 
neurodegenerative disease such as AD by generating a novel Tg mouse model (part 1), 
and I also tested potential of tau-targeting drug, which has been originally discovered 
(part 2). Tau, a MT protein is a key molecule in neurodegenerative diseases because it is 
accumulated as NFTs in a diseased brain and mutations in tau gene is known to cause a 
familial type of neurodegenerative disease (Hutton et al., 1998; Poorkaj et al., 1998; 
Spillantini et al., 1998). Toxicity of tau is not completely understood yet, however, 
hyperphosphorylation or mutations of tau is known to reduce the binding to MT 
through conformation change (Grundke-Iqbal et al., 1986; Goedert et al., 1995; Dan and 
Hasegawa., 2011). Detachment of tau from MT could destabilize MT and impair axonal 
function. Increased soluble pool of tau with mutation or hyperphosphorylation is prone 
to aggregate and it would damage neurons. Namely, mislocalization of tau might a key 
event in neurodegenerative diseases. 
 In part 1 of this study, a novel mutant tau Tg mouse TPR50 was generated and 
evaluated biochemically and behaviorally to analyze tau-induced neurotoxicity. TPR50 
mouse dramatically displayed neurodegenerative disease-like phenotype such as 
age-dependent tau aggregation, motor dysfunction, and shortened life expectancy 
(Figures 1, 4 and 5, and Supplementary Figure 2). Additionally, impaired axonal 
transport as well as behavioral abnormality was clearly observed at early onset (Figures 
6 and 9). Interestingly, as axonal dysfunction precedes obvious appearance of NFT-like 
pathology, increase in soluble and phosphorylated tau may perturb axonal function. 
Actually, it has been recently emphasized that soluble tau like oligomers plays an 
important role in neuronal dysfunction (Wittmann et al., 2001; SantaCruz et al., 2005; 
Cárdenas-Aguayo Mdel et al., 2014). Although molecular mechanism underlying axonal 
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impairment in TPR50 is still unknown, overexpressed mutant tau may interfere in 
function of endogenous tau and induce axonal dysfunction. In this study, MT 
hyperdynamism and increase in MT-related proteins were observed (Figures 7 and 8). 
Those observations might reflect imbalanced turnover of MT due to overload of mutant 
tau. Based on this result, it is hypothesized that targeting mislocalization of tau could 
be a promising therapeutic approach via reducing intracellular soluble tau oligomers 
and rescuing axonal function.  
 As one of candidate therapeutic approaches, inhibition of tau phosphorylation was 
focused in part 2. I discovered a novel inhibitor for GSK-3, a major kinase for tau, by 
efforts in the high-throughput screening and chemistry modification, and named 
MMBO. MMBO displays good selectivity for GSK-3, bioavailability, and brain 
permeability (Saitoh et al., 2009b and Table 2). Moreover, MMBO significantly showed 
therapeutic potential with reduction of tau phosphorylation and behavioral 
amelioration in AD mouse model (Figures 13 and 16), suggesting inhibition of tau 
phosphorylation would be a valid therapeutic strategy for AD as per the hypothesis. 
Regarding tau accumulation, MMBO did not change HT7-positive (total tau) pathology 
significantly (Figure 14). Therefore, observed behavioral amelioration could be 
dependent on reduction of soluble phosphorylated tau rather than effect of tau 
aggregate. This is consistent with my observation in TPR50 in part 1. In this study, I did 
not examine effect of MMBO on axonal transport or MT function. However, recent paper 
indicated that overexpression of tau with phosphomimetic mutations impaired axonal 
transport of mitochondria greater than WT tau (Shahpasand et al., 2012), suggesting 
that inhibition of tau phosphorylation might improve axonal function. Interestingly, 
pathological tau can enhance KLC phosphorylation by GSK-3 through activation of PP1 
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and following GSK-3 activation. KLC phosphorylation dissociates kinesin from cargo 
vesicles and impairs kinesin-dependent axonal transport (LaPointe et al., 2009; Kanaan 
et al., 2011). Namely, GSK-3 activation and consequent tau phosphorylation could lead 
to a vicious circle on axonal function. While, regarding dynein-dependent retrograde 
transport, tau accumulation might also impair it by affecting dynein/dynactin complex 
as reported by the recent study using flies (Butzlaff et al., 2015). Future study using 
MMBO will clarify relationship between tau phosphorylation and axonal function and 
the mechanism of action in its therapeutic effect.  
 In conclusion, improvement of axonal dysfunction due to abnormal tau is a novel 
therapeutic concept in neurodegenerative diseases such as AD, and inhibition of tau 
phosphorylation is a promising approach based on the concept.  
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